Skip to content
Review

The Association Between Reversion of Prediabetes to Normoglycemia and Incident Cardiovascular Disease and Mortality: A Systematic Review and Meta-Analysis.

Aug 2026 · Canadian Journal of Diabetes · 0 citations
Medicine

TL;DR

Reversion from prediabetes to normoglycemia is associated with significant reductions in cardiovascular events and cardiovascular mortality, supporting early identification and management of prediabetes as a cardiovascular prevention strategy.

Abstract

Background

Prediabetes affects approximately 470 million adults worldwide and is an established risk factor for cardiovascular disease. Whether reversion from prediabetes to normoglycemia reduces cardiovascular risk remains uncertain. We conducted a systematic review and meta-analysis to quantify this association with major cardiovascular events, cardiovascular mortality, and all-cause mortality.

Methods

We searched PubMed, Embase, CENTRAL, Web of Science, and Scopus through February 2026 for cohort studies and post-hoc analyses of randomized trials comparing cardiovascular outcomes in adults who reverted from prediabetes to normoglycemia versus persistent prediabetes. Hazard ratios were pooled using a DerSimonian-Laird random-effects model, with Hartung-Knapp-Sidik-Jonkman (HKSJ) sensitivity analysis. Heterogeneity was assessed using I2. Publication bias was evaluated using Egger's test.

Results

Seven studies (71,143 participants; follow-up 2-30 years) were included. Reversion to normoglycemia was associated with significantly lower composite cardiovascular events (HR 0.72, 95% CI 0.57-0.90; P = 0.004; I2 = 76.1%) and cardiovascular mortality (HR 0.69, 95% CI 0.51-0.95; P = 0.023; I2 = 65.5%). No significant association was found for all-cause mortality (HR 0.95, 95% CI 0.88-1.02; P = 0.169). The 95% prediction interval for the primary outcome ranged from 0.37 to 1.39. Leave-one-out sensitivity analysis confirmed result stability. Egger's test showed no publication bias (P = 0.36).

Conclusion

Reversion from prediabetes to normoglycemia is associated with significant reductions in cardiovascular events and cardiovascular mortality, supporting early identification and management of prediabetes as a cardiovascular prevention strategy. The observational nature of the evidence and wide prediction interval warrant cautious interpretation.

View source

Similar papers

Review Open access Sep 2026

Mortality and Cardiovascular Outcomes Associated with Statin Use in Dialysis Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.

INTRODUCTION Dialysis patients with established atherosclerotic cardiovascular disease (ASCVD) face exceptionally high risks of mortality and recurrent cardiovascular events, yet remain substantially underrepresented in major statin trials. We aimed to synthesize evidence from studies restricted to this population to e...

K. Chienwichai, Pannawat Mongkolrattanakul, Arunchai Chang et al. · 0 citations
Review Open access Sep 2026

Association Between Rest-Activity Rhythm and Cardiovascular Disease, Cardiovascular Mortality, and All-Cause Mortality: A Systematic Review and Meta-Analysis.

BACKGROUND Disruption in rest-activity rhythm (RAR) is an emerging risk factor for cardiovascular disease (CVD) and mortality, but the strength of evidence is unclear. Therefore, we conducted a systematic review and meta-analysis to assess associations between RAR characteristics and cardiovascular disease incidence or...

Feng-Shuo Chang, Jin-Hao Xu, M. Guo et al. · 0 citations
Meta-analysis Open access Sep 2026

Linking the triglyceride-glucose index to major adverse cardiocerebrovascular events in individuals with cardiovascular-kidney-metabolic syndrome: insights from an aggregate-data systematic review and dose–response meta-analysis

Background Epidemiological research has indicated a potential association between the triglyceride-glucose (TyG) index and the risk of major adverse cardiocerebrovascular events (MACCE). Nevertheless, the precise nature and magnitude of this relationship remain to be fully elucidated. Objectives This study aims to asse...

Lei-Lei Liu, Ting-Ting Yang, Lin-Yuan Zhang et al. · 0 citations
Review Sep 2026

Prediabetes: Impact on cardiovascular risk and emerging therapeutic strategies.

Prediabetes is a clinically relevant cardiometabolic state and its role as an independent CV therapeutic target remains uncertain, but future trials should address phenotype-specific risk stratification and evaluate contemporary cardiometabolic therapies in appropriately powered populations.

F. Biondi, S. Ghelardoni, E. Monti et al. · 0 citations
Open access Sep 2026

The prognostic value of eGDR in prediabetes outcomes: a sex-stratified prospective cohort study

Prediabetes is a critical phase that precedes the development of diabetes, characterized by insulin resistance as a key driver of its advancement. The estimated glucose disposal rate (eGDR) reflects insulin sensitivity, but its sex-specific prognostic value is uncertain. We analyzed a prospective cohort of...

Ying Yang, Jing-Qi Yang, Yu-Na Du et al. · 0 citations
Review Open access Sep 2026

Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis

Objective To compare cardiovascular and renal benefits and safety of GLP-1RAs, SGLT2is, and nsMRAs in T2D-CKD using network meta-analysis. Methods RCTs published through 7 August 2026 were systematically identified. A frequentist random-effects network meta-analysis was performed. Evidence certainty was assessed with C...

Hong-Li Chen, Xue-Jie Wu, M. Yuan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.